Cargando…

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Detalles Bibliográficos
Autores principales:	Richter, Joshua, Ailawadhi, Sikander, Lee, Hans C., Hardin, James W., Terebelo, Howard R., Abonour, Rafat, Wagner, Lynne I., Durie, Brian G.M., Omel, James L., Narang, Mohit, Toomey, Kathleen, Rifkin, Robert M., Gasparetto, Cristina J., Yu, Edward, Anand, Jasmeet, Liu, Liang, Jou, Ying-Ming, Jagannath, Sundar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology. Published by Elsevier Inc. 2022
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665177/ http://dx.doi.org/10.1182/blood-2022-158627

Ejemplares similares

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2020)

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry
por: Abonour, Rafat, et al.
Publicado: (2020)

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
por: Abonour, Rafat, et al.
Publicado: (2023)

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
por: Abonour, Rafat, et al.
Publicado: (2018)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Recognition of early mortality in multiple myeloma by a prediction matrix
por: Terebelo, Howard, et al.
Publicado: (2017)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
por: Wang, Bo, et al.
Publicado: (2020)

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
por: Costello, Caitlin, et al.
Publicado: (2019)

S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lee, Hans C., et al.
Publicado: (2023)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

1st International Conference of IFToMM Italy
por: Boschetti, Giovanni, et al.
Publicado: (2017)

Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
por: Jagannath, Sundar
Publicado: (2009)

NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Global disparities in patients with multiple myeloma: a rapid evidence assessment
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
por: Liu, Enze, et al.
Publicado: (2023)

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
por: Yang, Jay, et al.
Publicado: (2012)

Recent Advances in the Understanding and Treatment of Multiple Myeloma
por: Cook, Richard, et al.
Publicado: (2008)

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
por: Atrash, Shebli, et al.
Publicado: (2022)

Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study
por: Lu, Jin, et al.
Publicado: (2016)

P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)
por: Paiva, Bruno, et al.
Publicado: (2023)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
por: Girnius, Saulius K., et al.
Publicado: (2023)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
por: Paiva, Bruno, et al.
Publicado: (2023)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m9k34daqfo0irii4us0kr4ff5g